Crescent Capital BDC, Inc. filings document the regulatory record of a business development company that invests in secured debt, unsecured debt and related equity securities of private U.S. middle-market companies. Its Form 8-K reports include operating and financial results, dividend announcements, material agreements, capital-structure disclosures and other material events.
Proxy materials describe annual meeting voting matters, board governance and director elections. The filing record also identifies the company’s registered securities, including common stock listed under CCAP and exchange-listed notes, and provides formal disclosure around governance changes, shareholder matters, risk topics and financing arrangements.
Crescent Capital BDC, Inc. reported first quarter 2026 net investment income of $0.42 per share and a net loss of $0.42 per share, reflecting realized and unrealized losses on investments. Net asset value per share declined to $18.27 from $19.10 at year-end 2025.
The Board declared a regular second quarter 2026 cash dividend of $0.34 per share and special cash dividends totaling $0.09 per share, payable in three $0.03 installments. After quarter-end, the company reduced its base management fee to 1.00% and incentive fee to 15.0%, aiming to better align economics with shareholders.
CCAP’s quarterly report details an extensive portfolio of mainly floating-rate private credit investments. The holdings are concentrated in United States debt investments, with numerous unitranche first lien and senior secured first lien term loans, revolvers, and delayed draw term loans across software, health care, commercial services, and other sectors.
Many loans are priced at spreads such as S + 450 to S + 775, with stated cash interest rates often between about 8% and 12%, sometimes including additional PIK components. Maturities and revolver commitment expirations generally fall between 2026 and 2033, indicating a predominantly medium- to long-dated credit book with some international exposure in Europe, Canada, and Australia and a mix of common and preferred equity positions.
Crescent Capital BDC, Inc. reported board changes. Effective May 5, 2026, the board accepted the resignation of Class III director Elizabeth Ko, who stated her decision was not due to any disagreement with management, the board, or company operations.
Effective May 7, 2026, the board elected Chief Executive Officer Jason Breaux and President Henry Chung as Class III directors, whose terms run until the 2027 annual meeting or until successors are elected and qualified. Breaux will serve as Chairman of the Board. Neither Breaux nor Chung will receive compensation or equity awards for board service, and both will continue in their existing executive roles.
Crescent Capital BDC, Inc. is calling a fully virtual 2026 annual stockholders meeting on May 15, 2026, at 10:00 a.m. Pacific Time. Stockholders will vote on electing Class II directors Susan Yun Lee and Michael S. Segal to terms running to the 2029 meeting and on ratifying Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date is March 18, 2026, when 36,969,285 common shares were outstanding, with one vote per share. The Board and all independent directors unanimously recommend voting FOR both director nominees and FOR ratification of E&Y. The proxy also outlines governance structure, committee responsibilities, related-party advisory and administration agreements, and the external management fee and incentive fee arrangements with Crescent Cap Advisors, LLC.
Crescent Capital BDC, Inc. has issued two new series of senior unsecured notes and arranged a third under a note purchase supplement. The supplement covers up to $67.5 million of Tranche A notes due February 13, 2029, $67.5 million of Tranche B notes due February 13, 2031, and $50.0 million of Tranche C notes due May 22, 2029.
The Tranche A notes carry a fixed rate of 5.87% and the Tranche B notes a fixed rate of 6.20%. The Tranche A and Tranche B notes were issued on February 13, 2026, while issuance of the Tranche C notes is expected on May 22, 2026, subject to customary closing conditions.
To manage interest exposure, the company entered into interest rate swaps on each of Tranche A and Tranche B for notional amounts of $67.5 million. For Tranche A it will receive fixed 5.87% and pay three month term SOFR plus 2.5325% through February 13, 2029. For Tranche B it will receive fixed 6.20% and pay three month term SOFR plus 2.8050% through February 13, 2031.
Crescent Capital BDC (CCAP) provides a detailed look at its investment portfolio, which is heavily focused on privately negotiated debt across U.S. and international middle‑market companies. The schedule lists numerous unitranche, senior secured first lien, and second lien term loans and revolvers.
Borrowers span sectors such as health care services, software and IT, insurance, consumer services, commercial and professional services, industrials, and financials, with selected exposure in Europe and Australia. Most instruments reference floating base rates with contractual spreads and, in many cases, PIK (payment‑in‑kind) components, and have maturities extending broadly from 2025 into the early 2030s.
The portfolio also includes delayed draw term loans, unsecured PIK debt, foreign currency exchange contracts with Wells Fargo Bank, and a range of equity positions and partnership interests, giving CCAP a mix of income‑generating loans and potential equity upside.
Crescent Capital BDC, Inc. reported lower results for the year ended December 31, 2025, with net investment income of $1.81 per share and net income of $0.93 per share, down from $2.40 and $1.99 per share in 2024. Investment income fell to $167.3 million from $197.4 million, mainly because benchmark interest rates declined and certain debt investments were restructured. Net asset value per share declined to $19.10 from $19.98 as credit marks and foreign currency hedges weighed on results. For the fourth quarter of 2025, net investment income was $0.45 per share and net income was $0.23 per share. The company’s board declared a regular cash dividend of $0.42 per share for the first quarter of 2026, payable April 15, 2026 to shareholders of record on March 31, 2026. At year-end, Crescent BDC held $1.57 billion of investments across 184 portfolio companies, a weighted average yield on income-producing securities of 10.0%, and a debt-to-equity ratio of 1.25x, supported by $31.5 million of cash and $242.0 million of undrawn credit capacity.
Texas County & District Retirement System reports a significant passive stake in Crescent Capital BDC, Inc. It beneficially owns 5,001,752 shares of common stock, representing 13.50% of the class as of 12/31/2025.
The fund has sole power to vote and dispose of all 5,001,752 shares, with no shared voting or dispositive power. It certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Crescent Capital BDC.
Crescent Capital BDC, Inc. (CCAP) reported an insider share purchase by its Chief Financial Officer on a Form 4. On 11/17/2025, the CFO bought 2,000 shares of common stock in an open market transaction coded as a purchase.
The weighted average purchase price was $13.3415 per share, with individual trades executed between $13.34 and $13.3499. After this transaction, the CFO beneficially owned 34,284 shares of CCAP common stock.
This total includes 2,627 shares acquired during 2025 through dividend reinvestment that had not been previously reported. The filing notes that full trade price details are available to regulators, the company, or any security holder upon request.
Crescent Capital BDC, Inc. filed an 8-K to report that it issued a press release with its financial results for the quarter ended September 30, 2025. The company furnished the full text of this earnings press release as Exhibit 99.1. The information in this section, including the exhibit, is being treated as furnished rather than filed under securities law, which affects how it is incorporated into other regulatory documents.